Skip to content

Thank you to our Sponsors

interested in becoming one too?

The work of M4RD relies on the generous contributions of sponsors.

In 2013, Students4RareDiseases (our original name) was grateful to receive funding from Sanofi Genzyme by working with The UK LSD Collaborative. They received the PAL Award for the project “Hear hooves…Think Zebra” and thanks to this award we transformed a small student society into a national organisation.  Since then different parts of the project have received sponsorship from different companies.

We are currently working on our 2022 campaign – building on the success of 2021: adding to Rare Disease 101 with the launch of mini-modules and ‘deep-dive’ modules;  our online annual symposium, ‘The Unusual Suspects’; the publication of a Best Practice Guide for PAGs to engage with HCPS; another season of our popular podcast series; a series of webinars with the RSM’s Medicine & Me section on lessons learned from the COVID-19 pandemic in collaboration with the ARDEnt group; and many more projects. 

We would like to thank all our sponsors and donors for their generous support. Rather than targeting resources on one specific disease they understand that one part of achieving earlier diagnoses is by breaking down the stigma of rare diseases in healthcare. The work of M4RD will benefit all rare diseases.

If you would like to be a part of this change, please get in touch.

2022 Sponsors

2021 Sponsors

Alexion

Amicus Therapeutics

BioMarin

Bionical Emas

Freeline

Illumina Corporate Foundation

PTC Therapeutics

Sarepta Therapeutics

SOBI

 

2021 Donors

Takeda

 

2020 Sponsors

Alexion

Amicus

Sanofi Genzyme

SOBI

 

2020 Donors

BioMarin

Takeda

Ultragenyx

2019 Sponsors

BioMarin

Inventiva

SOBI

2018 Sponsors

BioMarin

Inventiva

SOBI

Ultragenyx

All funding received is used for achieving the objects of Medics4RareDiseases. M4RD seeks funding from commercial companies with an interest in rare disease including pharmaceutical companies.

The interaction between pharmaceutical companies and patient organisations is regulated by the Association of the British Pharmaceutical Industry’s Code of practice (ABPI Code) in order to protect the public. The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner. Medics4RareDiseases is committed to ensuring its activities and partnerships are compliant with the code. Please take time to find out more here.

M4RD does not endorse any companies or products. M4RD is operated independently from these companies and they have no editorial control over M4RD’s content or activities. M4RD’s mission is in raising awareness and any information on this website does not constitute medical advice.